Current Opinion in Lipidology

Papers
(The TQCC of Current Opinion in Lipidology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Editorial introductions76
Familial hypercholesterolemia-Plus: is the metabolic syndrome changing the clinical picture of familial hypercholesterolemia?63
Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease61
Alveolar macrophages: guardians of the alveolar lipid galaxy57
Genetic variation in apolipoprotein A-V in hypertriglyceridemia42
Ups and downs in PCSK9 inhibition in the cardiovascular arena: a review42
Angiopoietin-like protein 8: a multifaceted protein instrumental in regulating triglyceride metabolism37
The lipid-heart hypothesis from the Seven Countries Study of Cardiovascular Diseases34
Oxidized LDL receptors: a recent update32
Lipoprotein(a) and peripheral artery disease: contemporary evidence and therapeutic advances26
Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-1923
Implementation science and genetic testing for familial hypercholesterolemia19
Universal screening for familial hypercholesterolaemia: how can we maximise benefits and minimise potential harm for children and their families?18
Exosomes and lipid metabolism in metabolic and cardiovascular disorders17
Lipid metabolism during pregnancy: consequences for mother and child17
Familial hypercholesterolemia in children and the importance of early treatment17
Editorial introductions16
A new SPRING in lipid metabolism16
Nonalcoholic fatty liver disease: an update16
Nutrition and its impact on cardiovascular disease15
Genetic determinants of pancreatitis risk in hypertriglyceridemia14
The current state of apolipoprotein E in dyslipidemia14
The intracellular chylomicron highway: novel insights into chylomicron biosynthesis, trafficking, and secretion14
Familial hypercholesterolemia in pregnancy14
The need for national and international registries of patients with elevated lipoprotein(a)14
The complex pro-atherosclerotic role of lipoprotein(a): a multiplicity of cellular targets13
From clinical development to real-world outcomes with inclisiran13
Editorial introductions13
APOE and familial hypercholesterolemia12
ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?12
High-density lipoprotein functionality, cardiovascular health, and patterns of alcohol consumption: new insights and future perspectives12
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?12
Evolving guidelines on lipoprotein(a)11
Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent11
Cardiomyocytes, sphingolipids and cardio myotoxicity10
Editorial introductions10
Can small dense LDL cholesterol be estimated from the lipid profile?10
Distinct roles of size-defined HDL subpopulations in cardiovascular disease9
The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease9
The emerging role of fat-inducing transcript 2 in endoplasmic reticulum proteostasis and lipoprotein biogenesis9
Newborn screening for lipid disorders8
Beyond cholesterol: linking the conformation of apolipoprotein B to atherogenesis8
Strategies for management of patients with elevated lipoprotein(a)8
In the wake of the Scandinavian Simvastatin Survival Study trial8
Genetic testing for familial hypercholesterolemia7
Pregnancy, cardiovascular health, and microchimerism7
Circulating protein and lipid markers of early sepsis diagnosis and prognosis: a scoping review7
Clinical associations between exercise and lipoproteins7
Altered cardiovascular risk pattern of LDL cholesterol in older adults7
0.036849975585938